Sage Journals: Discover world-class research

Abstract

The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme consists of three randomised, double-masked, parallel, placebo-controlled studies to determine the impact of treatment with candesartan on diabetic retinopathy. In Type 1 diabetes, 1,700 patients without retinopathy will be randomised into a primary prevention study, and 1,200 with non-proliferative retinopathy into a secondary prevention study. In Type 2 diabetes, 1,600 patients with non-proliferative retinopathy will be randomised. Patients will be followed for at least three years. Eligible patients must be normotensive (systolic blood pressure [SBP] ≤ 130 mmHg and diastolic blood pressure [DBP] ≤ 85 mmHg) without antihypertensive medication in Type 1 diabetes, and either normotensive or treated hypertensive (SBP ≤ 160 mmHg and SBP ≤ 90 mmHg) and not taking angiotensin-converting enzyme inhibitors or AT₁receptor blockers in Type 2 diabetes. All patients will be normoalbuminuric, based on two overnight urine collections. The primary endpoint is based upon retinal photographs, graded to the Early Treatment of Diabetic Retinopathy Study scale. A two-step increase on this scale defines incidence, and a three-step increase defines progression of retinopathy. The main secondary endpoint for each study is change in urinary albumin excretion rate. A positive outcome of the DIRECT Programme would be an important step forward in the clinical management of patients with diabetes.

Keywords

diabetes diabetic retinopathy diabetic nephropathy angiotensin II type 1 receptor blocker candesartan

Get full access to this article

View all access options for this article.

References

Dwyer MS , Melton LJ , Ballard DJ , Palumbo PJ , Trautmann JC , Chu CP Incidence of diabetic retinopathy and blindness: a population-based study in Rochester, Minnesota . Diabetes Care 1985 ;8:316-22.

Klein R. , Klein BE , Moss SE , Davis MD , DeMets DL The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years . Arch Ophthalmol 1984;102:520-6.

Sjolie AK , Stephenson J. , Aldington S. et al. Retinopathy and vision loss in insulin-dependent diabetes in Europe.The EURO-DIAB IDDM Complications Study . Ophthalmology 1997;104: 252-60.

Evans J. , Rooney C. , Ashwood F. , Dattani N. , Wormald R. Blindness and partial sight in England and Wales: April 1990- March 1991 . Health Trends 1996;28:5-12.

Klein R. , Klein BE , Moss SE , Davis MD , DeMets DL The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years .Arch Ophthalmol 1984;102:527-32.

UK Prospective Diabetes Study. XII. Differences between Asian, Afro-Caribbean and white Caucasian type 2 diabetic patients at diagnosis of diabetes. UK Prospective Diabetes Study Group . Diabet Med 1994;11:670-7.

The Diabetic Retinopathy Study Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings . Ophthalmology 1978;85:85-106.

Amiel SA Diabetic control and complications . BMJ 1993 ;307:881-2.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33).UK Prospective Diabetes Study (UKPDS) Group . Lancet 1998;352: 837-53.

10.

Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group . Am J Med 1991;90:450-9.

11.

Klein R. , Klein BE , Moss SE , Davis MD , DeMets DL

Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?

Arch Intern Med 1989;149:2427-32.

12.

Chaturvedi N. , Sjolie AK , Stephenson JM et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes.The EUCLID Study Group. EURO-DIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus .Lancet 1998;351:28-31.

13.

Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group . BMJ 1998;317:703-13.

14.

National Institutes of Health, National Heart L, Blood Institute NHBPEP. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. NIH 1997.

15.

Belcher G. , Hubner R. , George M. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension . J Hum Hypertens 2002;11(suppl 2):S85-S89.

16.

Lansang CM , Osei SY , Price DA et al. Renal haemodynamic and hormonal responses to the angiotensin II antagonist candesartan . Hypertension 2000 ;36:834-8.

17.

Early Treatment of Diabetic Retinopathy Study (ETDRS). Manual of Operations. ETDRS Coordinating Center, University of Maryland, Department of Epedemiology and Preventive Medicine Division of Clinical Investigation , 600 Wyndhurst Ave . Baltimore, Maryland 21210. Manual of Operations 1979.

18.

Early Treatment of Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic colour fundus photographs - an extension of the Modified Airlie House classification. EDTRS Report number 10 . Ophthalmology 1991;98:786-806.

19.

Early Treatment of Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS Report number 12 . Ophthalmology 1991 ;98:823-33.

20.

Ravid M. , Savin H. , Jutrin I. , Bental T. , Katz B. , Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive Type II diabetic patients . Ann Intern Med 1993;118:577-81.

21.

Ravid M. , Lang R. , Rachmani R. , Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus.A 7-year follow-up study . Arch Intern Med 1996;156:286-9.

22.

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group . N Engl J Med 1993;329: 977-86.

23.

Wang PH When should ACE inhibitors be given to normotensive patients with IDDM . Lancet 1997;349:1782-3.

24.

Mogensen CE , Keane WF , Bennett PH et al. Prevention of diabetic renal disease with special reference to microalbuminuria . Lancet 1995;346:1080-4.

25.

Brenner BM , Cooper ME , de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy . N Engl J Med 2001;345:861-9.

26.

Parving H-H. , Lehnert H. , Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes . N Engl J Med 2001;345:870-8.

27.

Lewis EJ , Hunsicker LG , Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes . N Engl J Med 2001;345:851-60.

28.

Goldberg AI , Dunlay MC , Sweet CS Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension . Am J Cardiol 1995; 75:793-5.

29.

Moan A. , Hoieggen A. , Seljeflot I. , Risanger T. , Arnesen H. , Kjeldsen SE The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity . J Hypertens 1996;14:1093-7.

30.

Rosenthal T. , Erlich Y. , Rosenmann E. , Cohen A. Effects of enalapril, losartan, and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat . Hypertension 1997 ;29:1260-4.

31.

Hollenberg NK , Sever PS The past, present and future of hypertension management: a potential role for AT1-receptor antagonists . NEnglJMed 2000;345:851-60.

32.

Morsing P. , Adler G. , Brandt-Eliasson U. et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin . Hypertension 1999;33:1406-13.

33.

Lacourciere Y. , Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose in truly hypertensive patients: A placebo controlled, forced titration study . Am J Hypertens 1999;12:1181-7.

34.

Nagisa Y. , ShintaniA, Nakagawa S. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats . Diabetologia 2001;44:883-8.

35.

Klein R. , Klein BEK , Moss SE How many steps of progression of diabetic retinopathy are meaningful? The Wisconsin Epidemiologic Study of Diabetic Retinopathy . Arch Ophthalmol 2001;119:547-53.

36.

Sy JP , Taylor JM , Cumberland WG A stochastic model for the analysis of bivariate longitudinal AIDS data . Biometrics 1997;53:542-55.

The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme,rationale and study design

Abstract

Keywords

Get full access to this article

References